Patents by Inventor James Fandl
James Fandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210340564Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: July 2, 2021Publication date: November 4, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 11085053Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: September 10, 2019Date of Patent: August 10, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20210009714Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Publication number: 20200063159Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: September 10, 2019Publication date: February 27, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 10457959Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: July 31, 2017Date of Patent: October 29, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20180118852Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: September 11, 2017Publication date: May 3, 2018Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Publication number: 20170335341Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: July 31, 2017Publication date: November 23, 2017Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 9758592Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: GrantFiled: November 14, 2013Date of Patent: September 12, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Patent number: 9732357Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: August 19, 2015Date of Patent: August 15, 2017Assignee: REGENERON PHARMACEUTICALSInventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20160053280Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: August 19, 2015Publication date: February 25, 2016Inventors: Dipali DESHPANDE, Darya BURAKOV, Gang CHEN, James FANDL
-
Publication number: 20140134719Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: November 14, 2013Publication date: May 15, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: DIPALI DESHPANDE, GANG CHEN, DARYA BURAKOV, JAMES FANDL, THOMAS ALDRICH, VISHAL KAMAT
-
Publication number: 20070280945Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: June 1, 2007Publication date: December 6, 2007Inventors: Sean Stevens, Tammy Huang, Joel Martin, Jeanette Fairhurst, Ashique Rafique, Eric Smith, Kevin Pobursky, Nicholas Papadopoulos, James Fandl, Gang Chen, Margaret Karow
-
Publication number: 20060234311Abstract: A method of detecting and isolating cells that produce any secreted protein of interest (POI), comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.Type: ApplicationFiled: May 15, 2006Publication date: October 19, 2006Applicant: Regeneron Pharmaceuticals, Inc.Inventors: James Fandl, Neil Stahl, Gang Chen, George Yancopoulos
-
Publication number: 20060148705Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.Type: ApplicationFiled: February 2, 2006Publication date: July 6, 2006Inventors: Thomas Daly, James Fandl, Nicholas Papadopoulos
-
Publication number: 20060107341Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.Type: ApplicationFiled: January 13, 2006Publication date: May 18, 2006Inventor: James Fandl
-
Publication number: 20060030529Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.Type: ApplicationFiled: September 1, 2005Publication date: February 9, 2006Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
-
Publication number: 20050260203Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.Type: ApplicationFiled: March 25, 2005Publication date: November 24, 2005Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
-
Publication number: 20050186623Abstract: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.Type: ApplicationFiled: April 5, 2005Publication date: August 25, 2005Inventors: James Fandl, Neil Stahl, Gang Chen, George Yancopoulos
-
Publication number: 20050158829Abstract: A fusion polypeptide comprising (A)x—M—(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragmetns, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: ApplicationFiled: January 14, 2005Publication date: July 21, 2005Inventors: James Fandl, Gang Chen, Nicholas Papadopoulos, Thomas Aldrich
-
Publication number: 20050043236Abstract: Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.Type: ApplicationFiled: June 29, 2004Publication date: February 24, 2005Inventors: Thomas Daly, James Fandl, Nicholas Papadopoulos